GeNeuro's GNK-301 Shows Promise in Precision Medicine Approach for ALS
Key Insights
GeNeuro (search)'s GNK-301, a monoclonal antibody targeting HERV-K ENV (search), demonstrates potential in a precision medicine strategy for amyotrophic lateral sclerosis (search) (ALS (search)).
Preclinical studies indicate GNK-301 can detect HERV-K ENV (search), a neurotoxic protein, in cerebrospinal fluid of ALS (search) patients and neutralize its harmful effects.
The approach aims to protect neurons and prevent blood-brain barrier dysfunction, both hallmarks of ALS (search), offering a new treatment avenue.
GeNeuro (search) presented groundbreaking findings on its GNK-301, a potential precision medicine strategy for ALS (search), at the 35th International Symposium on ALS/MND in Montreal. The research highlights the potential of GNK-301, a humanized monoclonal antibody targeting HERV-K ENV (search), a neurotoxic protein found in the cerebrospinal fluid of ALS patients, to transform ALS treatment.
Targeting HERV-K ENV in ALS
Studies have demonstrated that HERV-K ENV (search) contributes to neuronal cell death and blood-brain barrier (BBB) dysfunction, both key features of ALS (search) pathology. GNK-301 can detect HERV-K ENV in cerebrospinal fluid samples and neutralize its harmful effects.
In preclinical studies, GNK-301 abolished the neurotoxicity of ALS (search) cerebrospinal fluid in iPSC-derived neuron cultures and neuronal death in mice injected with HERV-K ENV (search). The presence of HERV-K ENV in the brain also reproduced the BBB dysfunction observed in ALS brains, which was prevented by GNK-301. When labeled GNK-301 was injected intravenously in mice, it accumulated in brain regions where HERV-K ENV protein was present.
Clinical Implications and Future Directions
"We are excited to share these promising findings and congratulate the NIH/NINDS, ERBC and the University of Oxford for this exciting new data that opens a path towards a novel precision medicine approach in the treatment of sporadic ALS (search)," said Hervé Perron, CSO of GeNeuro (search).
Individuals with ALS (search) who produce endogenous autoantibodies against HERV-K ENV (search) tend to live longer, supporting the therapeutic potential of GNK-301. GNK-301 has a greater affinity and neutralizing effect compared to autoantibodies. The effect of HERV-K ENV on the BBB facilitates the transport of the antibody into brain tissue after intravenous administration.
GeNeuro (search) is planning for the required medical-grade production of GNK-301 to provide the antibody for clinical studies in ALS (search) patients who test positive for HERV-K ENV (search) using GeNeuro’s dedicated immunoassay. This represents the first integrated strategy for precision medicine in sporadic ALS.